Fisher Wallace Laboratories
Fisher Wallace Laboratories develops wearable brain-stimulation devices, sold directly to consumers, for anxiety, depression, and insomnia.
- 375
- Public company
- Brooklyn, NY, USUnited States
Fisher Wallace Laboratories develops wearable brain-stimulation devices, sold directly to consumers, for anxiety, depression, and insomnia.
fisherwallace.comCrawled Oct 15, 2026
The company’s sponges are made from natural cellulose and cut to fit Fisher Wallace Stimulator electrodes. The page advises replacing them when they show wear or discoloration and says orders placed today will ship next month.
The black lead wire that snaps onto a flexible electrode receptacle. To be used in conjunction with the Fisher Wallace Stimulator. NON-REFUNDABLE
The red lead wire that snaps onto a flexible electrode receptacle. To be used in conjunction with the Fisher Wallace Stimulator. NON-REFUNDABLE
Two flexible sponge receptacles for use in conjunction with the Fisher Wallace Stimulator device. Two (2) replacement sponges included. NON-REFUNDABLE
Fisher Wallace Labs creates better options to bolster stress and sleep management. Over 100,000 customers take advantage of scientifically validated technology.
Fisher Wallace secures millions in equity crowdfunding to develop new approaches in mental health treatment. The company targets alternative solutions for conditions often addressed by pharmaceutical interventions. Founders leverage crowdfunding to bypass traditional venture capital routes and accelerate product development.
Jun 2021MassDeviceNews article
Cranial electrotherapy stimulation (CES) devices are gaining traction as a treatment option for individuals managing anxiety, depression, and insomnia. The non-invasive technology applies mild electrical currents to the brain to help alleviate symptoms. Healthcare providers are now recommending CES as an alternative or complementary approach for patients seeking relief from these conditions.
Jan 2019Patient DailyNews article
Fisher Wallace Laboratories launches the Fisher Wallace Stimulator, a neurostimulation device now approved by New York City Health and Hospitals Corporation (NYC HHC). NYC HHC operates 11 major hospitals, including Bellevue, Woodhull, and Metropolitan, with Woodhull Hospital already integrating the device into patient care. The approval follows the device’s FDA clearance and expands its clinical adoption in urban healthcare settings.
Mar 2015BioSpaceNews article
Fisher Wallace Laboratories secures Health Canada approval for its portable Fisher Wallace Stimulator, a device targeting insomnia and chronic pain. The company, based in the US, markets the stimulator as a non-invasive treatment option for these conditions. Health Canada’s clearance follows regulatory review of its safety and efficacy claims.
May 2014Medical Device NetworkNews article